5 Pharmaceutical and biological preparations based on base editing, base modification, nucleobase editing, nucleobase modification, nucleic acid editing, gene editing, gene modification, gene modulation, gene reprogramming, gene therapy, genome editing, genome modification, cell therapy, cellular modification, tissue modification, and organ modification for use in human therapeutics for the treatment of Sickle Cell Disease, Beta Thalassemia, Alpha-1 Antitrypsin Deficiency, Glycogen Storage Disease Ia, Cancer, T-Cell Cancer, T-Cell Acute Lymphoblastic Leukemia, CD7 positive Acute Myeloid Leukemia, and Stargardt Disease
Trademark: 98209503
